• Immunohistochemistry of mouse Colon with Anti-SMAD4 primary antibody (STJ503059) at 1:100 dilution in Buffer. Section was treated with DAB and Haematoxylin stain. Magnification is at 40X.

Anti-SMAD4 antibody (131-181) (STJ503059)

SKU:
STJ503059-100

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: ELISA/IHC/IP/WB
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-SMAD4 (131-181) is suitable for use in ELISA, Immunohistochemistry, Immunoprecipitation and Western Blot research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Purification: Affinity Purified
Concentration: 0.6 µg/µl
Dilution Range: WB: 1:500
DB: 1:10, 000
ELISA: 1:10, 000
IP: 1:200
IHC: 1:50-1:150
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Gene Symbol: SMAD4
Gene ID: 4089
Uniprot ID: SMAD4_HUMAN
Immunogen Region: 131-181
Immunogen: Synthetic peptide taken within amino acid region 131-181 on human SMAD4 protein.
Post Translational Modifications Phosphorylated by PDPK1. Monoubiquitinated on Lys-519 by E3 ubiquitin-protein ligase TRIM33. Monoubiquitination hampers its ability to form a stable complex with activated SMAD2/3 resulting in inhibition of TGF-beta/BMP signaling cascade. Deubiquitination by USP9X restores its competence to mediate TGF-beta signaling.
Function In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions. Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling. Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site.required for synergistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.
Protein Name Mothers Against Decapentaplegic Homolog 4
Mad Homolog 4
Mothers Against Dpp Homolog 4
Deletion Target In Pancreatic Carcinoma 4
Smad Family Member 4
Smad 4
Smad4
Hsmad4
Database Links Reactome: R-HSA-1181150
Reactome: R-HSA-1502540
Reactome: R-HSA-201451
Reactome: R-HSA-2173789
Reactome: R-HSA-2173795
Reactome: R-HSA-2173796
Reactome: R-HSA-3311021
Reactome: R-HSA-3315487
Reactome: R-HSA-452723
Reactome: R-HSA-5689880
Reactome: R-HSA-8941326
Reactome: R-HSA-8941855
Reactome: R-HSA-8952158
Reactome: R-HSA-9615017
Reactome: R-HSA-9617828
Reactome: R-HSA-9733709
Reactome: R-HSA-9735871
Reactome: R-HSA-9754189
Reactome: R-HSA-9823730
Cellular Localisation Cytoplasm
Nucleus
Cytoplasmic In The Absence Of Ligand
Migrates To The Nucleus When Complexed With R-Smad
Pdpk1 Prevents Its Nuclear Translocation In Response To Tgf-Beta
Alternative Antibody Names Anti-Mothers Against Decapentaplegic Homolog 4 antibody
Anti-Mad Homolog 4 antibody
Anti-Mothers Against Dpp Homolog 4 antibody
Anti-Deletion Target In Pancreatic Carcinoma 4 antibody
Anti-Smad Family Member 4 antibody
Anti-Smad 4 antibody
Anti-Smad4 antibody
Anti-Hsmad4 antibody
Anti-SMAD4 antibody
Anti-DPC4 antibody
Anti-MADH4 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance